ArticleEuropean heart journal1988
Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia.
Article in European heart journal, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01634906 (Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy
Who cites it
16 citing papers in PubMed, 49 citations in OpenAlex.
- Simvastatin in severe hypercholesterolaemia: a placebo controlled trial.British journal of clinical pharmacology · 1991Trial
- Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia.European journal of clinical pharmacology · 1989Trial
- Autophagy-urea cycle pathway is essential for the statin-mediated nitric oxide bioavailability in endothelial cells.Journal of food and drug analysis · 2023Article
- The ocular toxicity and pharmacokinetics of simvastatin following intravitreal injection in mice.International journal of ophthalmology · 2017Article
- Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase.Scientific reports · 2015Article
- Antiangiogenic mechanisms of simvastatin in retinal endothelial cells.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2010Article
- ROCK as a Therapeutic Target of Diabetic Retinopathy.Journal of ophthalmology · 2010Article
- Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins.Diabetes · 2008Article
- Omega-3 Ethyl Ester Concentrate Decreases Total Apolipoprotein CIII and Increases Antithrombin III in Postmyocardial Infarction Patients.Clinical drug investigation · 1998Article
- Vitamins Q and E, extracorporal circulation and hemolysis.Molecular and cellular biochemistry · 1997Article
- Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin.Cardiovascular drugs and therapy · 1995Article
- Clinical pharmacokinetics and practical applications of simvastatin.Clinical pharmacokinetics · 1993Review
- Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.Cardiovascular drugs and therapy · 1992Article
- One year experience in the treatment of familial hypercholesterolaemia with simvastatin.Postgraduate medical journal · 1992Article
- Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden.PharmacoEconomics · 1992Article
- Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.Drugs · 1990Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of 24 weeks of treatment with simvastatin, a new HMG coenzyme A reductase inhibitor (dosages of 20 and 40 mg day-1) on serum lipid, lipoprotein and apolipoprotein A-I and B concentrations as well as safety parameters and subjective side effects were studied in 11 patients with familial (FH) and 10 patients with polygenic hypercholesterolaemia (P-HC). The effects on plasma lipoprotein and apolipoprotein concentrations had already been achieved after four weeks in both groups and then remained during the study. In FH, mean fasting plasma total cholesterol concentration decreased from 10.51 to 6.71 mmol l-1 (36%), and in P-HC from 6.55 to 4.54 mmol l-1 (31%) at 24 weeks (P less than 0.001). Mean plasma low density lipoprotein (LDL) cholesterol concentrations also decreased, in FH from 8.87 to 5.05 mmol l-1 (43%) and in P-HC from 4.97 to 3.12 mmol l-1 (37%) at 24 weeks (P less than 0.001). Furthermore, apolipoprotein B concentrations decreased significantly from 2.21 to 1.57 g l-1 (29%) (less than 0.001) in FH and from 1.53 to 1.09 g l-1 (29%) (P less than 0.01) in P-HC. Plasma high density lipoprotein (HDL) cholesterol increased in both FH and P-HC during treatment. Increases were seen in both the subfractions HDL2 and HDL3. Simvastatin was well tolerated. No serious clinical or laboratory adverse effects were observed. It is concluded that 24 weeks of treatment with simvastatin in doses up to 40 mg day-1 effectively reduces plasma total and LDL cholesterol concentrations without causing subjective or significant objective side effects. Thus, simvastatin may be of great interest in future studies for prevention of coronary heart disease due to hypercholesterolaemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.